Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922794 | 1.00 | CYP3A4 (0.55) | CYP3A4SLC7A5 | |
| SCHEMBL16363243 | 1.00 | CYP3A4 (0.55) | CYP3A4SLC7A5 | |
| SCHEMBL12982252 | 0.93 | CYP3A4 (0.48) | CYP3A4SLC7A5 | |
| SCHEMBL12982249 | 0.88 | CYP3A4 (0.58) | CYP3A4SLC7A5 | |
| SCHEMBL17697372 | 0.88 | CYP3A4 (0.58) | CYP3A4SLC7A5 | |
| SCHEMBL21099730 | 0.87 | CYP3A4 (0.57) | CYP3A4SLC7A5 | |
| SCHEMBL16192880 | 0.87 | CYP3A4 (0.61) | CYP3A4SLC7A5 | |
| SCHEMBL15246080 | 0.86 | CYP3A4 (0.43) | CYP3A4SLC7A5 | |
| SCHEMBL12234246 | 0.85 | CYP3A4 (0.61) | CYP3A4SLC7A5 | |
| SCHEMBL12982052 | 0.85 | CYP3A4 (0.49) | CYP3A4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320927-A1 | GLP-1 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-11-09 | — | — | US | disclosed |
| US-9751927-B2 | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use | NOVO NORDISK A/S (DK) | 2017-09-05 | — | — | US | disclosed |
| EP-3010546-B1 | GLP-1 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2017-08-09 | — | — | EP | disclosed |
| US-20170190757-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170114116-A1 | Double-Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170101454-A1 | GLP-1/Glucagon Receptor Co-Agonists for Medical Use | NOVO NORDISK A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170051034-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-02-23 | — | — | US | disclosed |
| US-20160355562-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | NOVO NORDISK AS (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160347812-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-12-01 | — | — | US | disclosed |
| US-20160271263-A1 | Acylated Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20130079278-A1 | Novel Glucagon Analogues | NOVO NORDISK A/S (DK) | 2013-03-28 | — | — | US | disclosed |
| US-20120172298-A1 | GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 | NOVO NORDISK A/S (DK) | 2012-07-05 | — | — | US | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| WO-2010142665-A1 | GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 | NOVO NORDISK A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| WO-2009030738-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030771-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008081418-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190757-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | CYP3A4 3381/4885SLC7A5 903/4885 |
| US-20170101454-A1 | GLP-1/Glucagon Receptor Co-Agonists for Medical Use | GLP1R, GCGR, GIPR | CYP3A4 1220/4885SLC7A5 3530/4885 |
| US-20130079278-A1 | Novel Glucagon Analogues | GLP1R, GCG, GCGR | CYP3A4 3244/4885SLC7A5 2692/4885 |
| US-20170114116-A1 | Double-Acylated GLP-1 Compounds | GLP1R, GIPR, HACD3 | CYP3A4 1592/4885SLC7A5 424/4885 |
| US-20160355562-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | GLP1R, GIPR, GCGR | CYP3A4 2983/4885SLC7A5 2521/4885 |
| US-20100305032-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | CYP3A4 3519/4885SLC7A5 1592/4885 |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | CYP3A4 3417/4885SLC7A5 1967/4885 |
| US-20160271263-A1 | Acylated Glucagon Analogues | GLP1R, GCG, IAPP | CYP3A4 3011/4885SLC7A5 962/4885 |
| US-20160347812-A1 | Novel Glucagon Analogues | GLP1R, GCG, GCGR | CYP3A4 3244/4885SLC7A5 2692/4885 |
| US-20170320927-A1 | GLP-1 Derivatives and Uses Thereof | GLP1R, GIPR, GCG | CYP3A4 4263/4885SLC7A5 1094/4885 |
| US-20170051034-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | CYP3A4 3381/4885SLC7A5 903/4885 |
| US-20120172298-A1 | GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 | GLP1R, IAPP, FGF1 | CYP3A4 3586/4885SLC7A5 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.